Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

Alzheimer's disease (AD) is conceptualized as a progressive consequence of two hallmark
pathological changes in grey matter: extracellular amyloid plaques and neurofibrillary …

Cellular perturbations underlying Alzheimer's disease (AD) are primarily studied in human
postmortem samples and model organisms. Here, we generated a single-nucleus atlas from …

Objective White matter hyperintensities (WMHs) are areas of increased signal on T2‐
weighted magnetic resonance imaging (MRI) scans that most commonly reflect small vessel …

Reduction of amyloid beta (Aβ) has been shown to be effective in treating Alzheimer's
disease (AD), but the underlying assumption that neurons are the main source of pathogenic …

Although Alzheimer's disease is the most pervasive neurodegenerative disorder, the
mechanism underlying its development is still not precisely understood. Available data …

Beta amyloid is a protein fragment snipped from the amyloid precursor protein (APP).
Aggregation of these peptides into amyloid plaques is one of the hallmarks of Alzheimer's …

Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of
Alzheimer's disease. It remains uncertain, however, how it relates to amyloid and tau …

Alzheimer's disease (AD) is one of the major disabling and lethal diseases for aged
individuals worldwide. To date, there are more than 10 hypotheses proposed for AD …

Endocannabinoids are important regulators of neurotransmission and, acting on activated
microglia, they are postulated as neuroprotective agents. Endocannabinoid action is …